News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Subscribe To Our Newsletter & Stay Updated
